by Manon FRACHON | 14 Nov Tue | English
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative retinal disease pipeline...
by Manon FRACHON | 12 Sep Tue | English
Paris, France, September 11th 2023 – Three years after being the 1st biopharma fund to be awarded the Tibi 1 label, Jeito Capital has announced that it has been renewed in the Tibi 2 selection, confirming its role as an accelerator in the financing of technology...
by Manon FRACHON | 7 Sep Thu | English
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs Jeito Capital marks its...
by Manon FRACHON | 13 Apr Thu | English
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development After its investment 2 years ago, Jeito Capital amplifies its...
by Manon FRACHON | 7 Mar Tue | English
Noema Pharma’s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital’s...
by Manon FRACHON | 6 Dec Tue | English
The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole. Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the...
Recent Comments